RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Axel Lehrer to Angiotensin-Converting Enzyme Inhibitors

Back to Details
This is a "connection" page, showing publications Axel Lehrer has written about Angiotensin-Converting Enzyme Inhibitors.
Axel Lehrer
Connection Strength
0.053
Angiotensin-Converting Enzyme Inhibitors
  1. Chen D, Yun X, Lee D, DiCostanzo JR, Donini O, Shikuma CM, Thompson K, Lehrer AT, Shimoda L, Suk JS. Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections. Mol Pharm. 2023 01 02; 20(1):750-757.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support